The Problem Of Tb Infection And Disease Management

Tuberculosis has long been a disease that the human culture has been dealing with which entails significant morbidity and mortality worldwide. With dealing with such a horrific disease over the years, discoveries and evolution on the appropriate ways to contain, diagnose, and challengingly treat the disease has changed. One of the most concerning complications of this worldwide public health issue is the ability for it to quickly spread in high populated areas while becoming ever more resistant to forms of treatment not available in all locations around the world. This is a serious public

Bacterial pathogen Mycobacterium tuberculosis causes tuberculosis a complex granulomatous disease which is a global health concern. It is a very slow growing bacteria, thus is extremely time consuming to culture in laboratory. It can survive the attack of the immune arsenal of our body; can successfully hide inside the macrophage. This makes long periods of uninterrupted antibiotic treatment necessary for the patients with tuberculosis and contributes to drug resistance very quickly [WHO 2014]. All this poses an extreme challenge to the scientists and the medical community to develop effective drug, monitor and treat this disease across globe. Before the discovery of anti-tubercular drugs, this disease was one of the most dreaded diseases. In absence of any drugs the only form of treatment recommended was healthy diet, rest and fresh air. Patients were sent to Tuberculosis sanatorium hoping that they might survive. The origin of this pathogen is traced back to Africa around 70,000 years ago and they successfully coevolved with humans as they migrated out of Africa and settled across the globe. Nearly 10,000 years ago there was a sudden change in human demography and the human population density increased suddenly, this is termed as Neolithic Demographic Transition. Genomic data of Mycobacterium across

“Tuberculosis (TB), a multisystem disease with myriad presentations and manifestations, is the most common cause of infectious disease–related mortality worldwide. Although TB rates are decreasing in the United States, the disease is becoming more common in many parts of the world. In addition, the prevalence of drug-resistant TB is increasing worldwide. TB is caused by M tuberculosis, a slow-growing obligate aerobe and a facultative intracellular parasite. The organism grows in parallel groups called cords (as seen in the image below). It retains many

Tuberculosis has been part of human history for a long time but how long is a long time? Recent research using genetic data has allowed us to know that the tuberculosis progenitor has been on this planet for about 3 million years affecting even our earlier ancestors (Gutierrez et al, 2005). Additionally this research showed that the bacilli from tuberculosis are capable of mixing sections of their genome with other strains and giving the pathogen a composite assembly, which resulted from ancient horizontal exchanges before its clonal expansion. This quality provided tuberculosis a big advantage that even now a days allows the organism to evade, adapt and create resistance to treatments that were once successful. In order to fix current and

Now, we will see what the most optimal solution to this recent problem in the classic epidemiological way, by understanding the history of TB, the drug-resistant strain’s origin, and recent cases of the disease.

Tuberculosis (Mycobacterium tuberculosis), also known as TB, is a disease spread by respiratory inhalation of droplets that contain the bacteria. Tuberculosis is an ancient disease that has been traced back at least 9000 years. In 1882, Dr. Robert Koch was the first physician to describe Mycobacterium tuberculosis as the germ responsible for tuberculosis. However, treatment that was evidenced based was not put into practice until the 20th century. It is estimated that 2 billion people around the world are infected with the TB bacteria. Approximately 5 to 10 percent of these infected people will actual develop active TB and experience the life-threatening symptoms of the disease. Tuberculosis

Health information: To create health information education tools and to increase information dissemination regarding TB and DM co-epidemic among staff and community

Tuberculosis, TB (tubercle bacillus) or MTB (mycobacterium tuberculosis) is a widespread, and in numerous cases fatal, communicable disease produced by a variety of forms of mycobacteria. The disease is distributed within the air when individuals who are infected with active TB infection sneeze, cough, or pass on breathing fluids throughout the air. Generally infections are asymptomatic, meaning they feel or show no symptoms, and dormant, but then again approximately one in ten dormant infections in the long run move on to the active disease. If left untouched, active TB is fatal to more than half of those infected.

In 2014, 72% of TB cases were found among people born outside the UK. India, Pakistan and Somalia were the most frequent countries of birth for non-UK born cases, though rates among this group have decreased significantly over the last two years. This decrease in rates is also true in the non-UK born population as a whole. TB remains an illness that is associated with health inequality. People in deprived communities have rates of TB seven times higher than people in the least deprived areas. 34% of cases were found among people not in education or

a patient with a new case of TB can be treated at home. Others will enter the

Tuberculosis (TB) is a CDC (Centers for Disease Control) notifiable disease which is caused by an infectious bacterium that was discovered by a man named Robert Koch in 1882. This infectious bacterium that causes Tuberculosis is called Mycobacterium tuberculosis (Mtb), and is also known as Koch 's Bacillus. According to the National Institute of Allergy and Infectious Diseases (2015), Mtb is a small, slow-growing bacterium that can live only in people. It is not found in other animals, insects, soil, or other non-living things. Mtb is an aerobic bacterium, which means

Progress tackling the TB burden is associated with Directly Observed Treatment – Short Course (DOTS) from the Stop TB Strategy, adopted by WHO in 1993. This strategy involves and addresses TB/HIV, multidrug-resistant TB and the needs of poor and vulnerable populations, strengthening primary care, engaging all care providers, empowering people with TB and communities with partnership, and enabling and promoting research. DOTS is a global TB control, reducing TB incidents by directly observing patients taking their drugs. Countries that have adopted the DOTS strategy have effectively treated a total of 51 million people since 1995 (The Global Fund To Fight AIDS, Tuberculosis and Malaria, 2014).

The purpose of this project was to educate Cambodian physicians, nurses, and medical technicians about current findings from other countries regarding the diagnoses and treatment of Tuberculosis (“TB”). In Cambodia many TB cases go undetected or untreated, and insufficient information is being distributed to the citizens, especially those living in rural areas. This project aims to address the causes, signs, symptoms, and treatment of TB so that the general population will have a better understanding of this deadly disease. The project will also inform community personnel—such as nuns, monks and other organizations—about TB since they are the first points of contact with the villagers. Additionally, in the project I trained and updated medical professionals about developments in the field of drug resistant TB. Trainings included the definition of drug resistance, the causes of drug resistance, and the ways to prevent the bacterium that cause TB from becoming drug resistant. I believe my project is of great importance, and will provide citizens with the information that they need about this infectious disease. Hopefully, this project will aid in decreasing the incidence rate of TB.

Tuberculosis is among the fatal diseases that are spread through the air. It’s contagious, meaning that it spreads from one infected individual to another, and at times it spreads very fast. In addition to being contagious, the disease is an opportunist infection as it takes advantage of those with weak defense mechanism, and especially the ones with terminal diseases like HIV and AIDS. Tuberculosis is therefore among the major concerns for the World Health Organization due to its contagious nature (World Health Organization 1).

In 2011, WHO estimated 12 million prevalent cases of tuberculosis worldwide, of which about 630 000 (roughly 5%) were MDR tuberculosis. The highest caseloads of MDR tuberculosis were reported in India, China, Russia, and South Africa, which accounted for more than 60% of cases worldwide. India and China have the highest number of MDR tuberculosis cases worldwide. Tuberculosis has now been made a notifiable disease in India. Drug resistance surveys in several states have indicated that the prevalence of MDR TB in India is 2–3 percent among new cases and 12-17 percent among reinfection cases. According to drug